AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20138095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18775608 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐estradiol
Number of subjects: 74
Study 18775608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive substance)
Number of subjects: 74
Study 16650417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PCOS
Number of subjects: 159
Study 16650417 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 159
Study 12879220 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (60 min per day, 3 days a week)
Number of subjects: 0
Study 12879220 — intervention group
Group type: COMPARATOR
Intervention: Control (usual activities)
Number of subjects: 0
Study 12879220 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 0
Study 11694861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice daily)
Number of subjects: 56
Study 10771880 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV (Inactivated Polio Vaccine)
Number of subjects: 0
Study 10771880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of IPV starting from birth
Number of subjects: 0
Study 10771880 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV/OPV at birth followed by 3 doses of OPV
Number of subjects: 0
Study 10771880 — intervention group
Group type: EXPERIMENTAL
Intervention: Some vaccine at birth (IPV or OPV)
Number of subjects: 0
Study 10771880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of IPV
Number of subjects: 0
Study 10771880 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV or OPV at birth
Number of subjects: 0
Study 8183102 — intervention group
Group type: COMPARATOR
Intervention: Sodium concentration of 0 mmol.l‐1
Number of subjects: 6
Study 8183102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium concentration of 25 mmol.l‐1
Number of subjects: 6
Study 8183102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium concentration of 50 mmol.l‐1
Number of subjects: 6
Study 3351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg (acute study)
Number of subjects: 19
Study 3351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 25 mg (chronic study)
Number of subjects: 19
Study 30669291 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (Fortaleça sua Saúde program)
Number of subjects: 548
Study 30669291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 548
Study 28688136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 84
Study 28688136 — intervention group
Group type: COMPARATOR
Intervention: Traditional palpation technique
Number of subjects: 84
Study 25823403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl) for 5 minutes followed by EDTA for 10 minutes
Number of subjects: 50
Study 25823403 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + triple antibiotic paste (TAP) for 4 weeks followed by EDTA
Number of subjects: 50
Study 25823403 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + diluted triple antibiotic paste (DTAP) for 4 weeks followed by EDTA
Number of subjects: 50
Study 25823403 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + calcium hydroxide (Ca[OH]2) for 4 weeks followed by EDTA
Number of subjects: 50
Study 25823403 — intervention group
Group type: COMPARATOR
Intervention: Untreated dentin
Number of subjects: 50
Study 25823403 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl + EDTA-treated dentin
Number of subjects: 50
Study 23307511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tα1 administration for 2 weeks
Number of subjects: 8
Study 23307511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tα1 administration)
Number of subjects: 8
Study 23307511 — intervention group
Group type: EXPERIMENTAL
Intervention: Tα1 administration
Number of subjects: 8
Study 21768905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) self-applied at mid-thigh level
Number of subjects: 24
Study 21768905 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) applied by a researcher
Number of subjects: 24
Study 21768905 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency and Military Tourniquet (EMT) applied
Number of subjects: 24
Study 19152135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99 m tetrofosmin SPECT myocardial perfusion imaging (MPI)
Number of subjects: 0
Study 19152135 — intervention group
Group type: COMPARATOR
Intervention: Exercise treadmill testing (ETT)
Number of subjects: 0
Study 16738024 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral styles after 2 weeks
Number of subjects: 102
Study 16738024 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral styles after 15 weeks
Number of subjects: 102
Study 16738024 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' perceptions of their own personalities
Number of subjects: 102
Study 15492601 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume tap water gastric lavage prior to esophagogastroduodenoscopy
Number of subjects: 39
Study 15492601 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy alone
Number of subjects: 39
Study 11406837 — intervention group
Group type: EXPERIMENTAL
Intervention: Education package for the treatment of menorrhagia given to doctors at a primary care level
Number of subjects: 0
Study 11406837 — intervention group
Group type: COMPARATOR
Intervention: No education package (control group)
Number of subjects: 0
Study 9265910 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 9265910 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 9265910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8219431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine with behavior modification
Number of subjects: 150
Study 8219431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine without behavior modification
Number of subjects: 150
Study 8219431 — intervention group
Group type: COMPARATOR
Intervention: Placebo with behavior modification
Number of subjects: 150
Study 8219431 — intervention group
Group type: COMPARATOR
Intervention: Placebo without behavior modification
Number of subjects: 150
Study 8219431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 150
Study 8219431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 30470924 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized immediate postpartum contraceptive counseling intervention emphasizing healthy birth spacing and LARC
Number of subjects: 100
Study 30470924 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum availability of the contraceptive implant
Number of subjects: 100
Study 30470924 — intervention group
Group type: COMPARATOR
Intervention: Subjects who desired the IUD
Number of subjects: 100
Study 29578520 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile game-based virtual reality program for upper extremity rehabilitation
Number of subjects: 0
Study 27187436 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare providers (HCPs)
Number of subjects: 500
Study 27187436 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children aged 6-10 and 11-14 years
Number of subjects: 500
Study 24057996 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TOP)
Number of subjects: 57
Study 24057996 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate/Nicotine patch (TOP/NIC)
Number of subjects: 57
Study 24057996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 57
Study 23018337 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture Conducive to Women's Academic Success (CCWAS) measure
Number of subjects: 133
Study 23018337 — intervention group
Group type: EXPERIMENTAL
Intervention: CCWAS dimensions: equal access, work-life balance, freedom from gender biases, supportive leadership
Number of subjects: 133
Study 20028376 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs)
Number of subjects: 7461
Study 20028376 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IgE
Number of subjects: 7461
Study 17986289 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence diagnosis (FD)
Number of subjects: 46
Study 17986289 — intervention group
Group type: COMPARATOR
Intervention: White light (WL)
Number of subjects: 46
Study 16471192 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOAE amplitude and slope of DPOAE input/output function after noise exposure
Number of subjects: 30
Study 16471192 — intervention group
Group type: EXPERIMENTAL
Intervention: SISI test results
Number of subjects: 30
Study 11960561 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack positioned at T7 with loads of 3%, 5%, or 10% of body weight
Number of subjects: 250
Study 11960561 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpack loads (3%, 5%, or 10% of body weight)
Number of subjects: 250
Study 11960561 — intervention group
Group type: COMPARATOR
Intervention: Unloaded standing posture (baseline)
Number of subjects: 250
Study 10394049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 0
Study 10394049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7676386 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing dentifrice (9.7%)
Number of subjects: 70
Study 7676386 — intervention group
Group type: COMPARATOR
Intervention: Non-xylitol-containing fluoride dentifrice
Number of subjects: 70
Study 2372267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily + Aspirin 600 mg three times a day
Number of subjects: 69
Study 2372267 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 69
Study 6108263 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate/pseudoephedrine sulfate
Number of subjects: 60
Study 6108263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31241208 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness induction
Number of subjects: 49
Study 31241208 — intervention group
Group type: EXPERIMENTAL
Intervention: Sadness induction
Number of subjects: 49
Study 31241208 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-ED)
Number of subjects: 49
Study 29987365 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (HT) for 30 min/day, 5 days/week for 4 weeks
Number of subjects: 60
Study 29987365 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training (NT) for 30 min/day, 5 days/week for 4 weeks
Number of subjects: 60
Study 29987365 — intervention group
Group type: COMPARATOR
Intervention: Hypoxic control (HC) for 30 min/day, 5 days/week for 4 weeks
Number of subjects: 60
Study 29987365 — intervention group
Group type: COMPARATOR
Intervention: Normoxic control (NC) for 30 min/day, 5 days/week for 4 weeks
Number of subjects: 60
Study 27133033 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise (group A)
Number of subjects: 44
Study 27133033 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-strength exercise (group B)
Number of subjects: 44
Study 24592904 — intervention group
Group type: EXPERIMENTAL
Intervention: Interseptal bone reduction combined with conventional orthodontic fixed appliance
Number of subjects: 18
Study 24592904 — intervention group
Group type: COMPARATOR
Intervention: Conventional extraction (control)
Number of subjects: 18
Study 22344575 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week
Number of subjects: 221
Study 22344575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 20620742 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol intervention (HiFI) [375 mg]
Number of subjects: 16
Study 20620742 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol intervention (LoFI) [9 mg]
Number of subjects: 16
Study 17079067 — intervention group
Group type: EXPERIMENTAL
Intervention: CPREzy
Number of subjects: 202
Study 17079067 — intervention group
Group type: EXPERIMENTAL
Intervention: CPREzy (Group 2A; n = 36)
Number of subjects: 202
Study 17079067 — intervention group
Group type: COMPARATOR
Intervention: Classic ECC (Group 2B; n = 55)
Number of subjects: 202
Study 16296913 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic remedy
Number of subjects: 43
Study 16296913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11927115 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (Mirena)
Number of subjects: 256
Study 9797692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 300 mg daily
Number of subjects: 47
Study 9797692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 150 mg daily
Number of subjects: 47
Study 9797692 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study 7572771 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation at He‐7 acupoint
Number of subjects: 0
Study 7572771 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture control point stimulation
Number of subjects: 0
Study 7572771 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture stimulation at LI‐4 acupoint
Number of subjects: 0
Study 2202024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte cannula (24 G)
Number of subjects: 500
Study 2202024 — intervention group
Group type: COMPARATOR
Intervention: Quincke cannula (25 G)
Number of subjects: 500
Study 64803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg and 10 mg
Number of subjects: 20
Study 64803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 2 mg three times daily (rising to 5 mg if required)
Number of subjects: 20
Study 64803 — intervention group
Group type: EXPERIMENTAL
Intervention: All three drugs (beta blockade, bendrofluazide, and prazosin)
Number of subjects: 20
Study 64803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 20
Study 64803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 20
Study 64803 — intervention group
Group type: COMPARATOR
Intervention: Beta blockade
Number of subjects: 20
Study 30793440 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of oxidized low-density lipoprotein (oxLDL)
Number of subjects: 3019
Study 30793440 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of oxidized low-density lipoprotein:high-density lipoprotein (oxLDL:HDL)
Number of subjects: 3019
Study 30793440 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of oxidized low-density lipoprotein:low-density lipoprotein (oxLDL:LDL)
Number of subjects: 3019
Study 29999596 — intervention group
Group type: EXPERIMENTAL
Intervention: nHFOV
Number of subjects: 30
Study 29999596 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 30
Study 26934136 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 165
Study 26934136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 24462960 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7% hypertonic saline solution supplemented with 40 mg furosemide (salt infusion group)
Number of subjects: 44
Study 24462960 — intervention group
Group type: COMPARATOR
Intervention: Glucose supplemented with 40 mg furosemide (glucose infusion group)
Number of subjects: 44
Study 22955125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (120 mg tablet, EGb‐761) twice a day for 12 weeks
Number of subjects: 120
Study 22955125 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet twice a day for 12 weeks
Number of subjects: 120
Study 20028712 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 10 mg twice a day
Number of subjects: 0
Study 20028712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17684983 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch
Number of subjects: 2
Study 17684983 — intervention group
Group type: COMPARATOR
Intervention: 10% albumin solution
Number of subjects: 2
Study 16084882 — intervention group
Group type: EXPERIMENTAL
Intervention: G972A variant of insulin receptor substrate‐1 (IRS‐1) in women with PCOS
Number of subjects: 120
Study 16084882 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without PCOS)
Number of subjects: 120
Study 12601100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (0.15 to 0.45 mg per day)
Number of subjects: 57
Study 12601100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 10029283 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFNalpha, 10 MU, i.m. daily for 2 consecutive weeks and then three times per week for the subsequent 14 weeks (total dose 560 MU)
Number of subjects: 50
Study 10029283 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural IFNalpha treatment
Number of subjects: 50
Study 8677203 — intervention group
Group type: EXPERIMENTAL
Intervention: Men after myocardial infarction
Number of subjects: 33
Study 8677203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sons of patients
Number of subjects: 33
Study 8677203 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 33
Study 8677203 — intervention group
Group type: COMPARATOR
Intervention: Control group (sons)
Number of subjects: 33
Study 1996510 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed reminders for all eligible patients
Number of subjects: 686
Study 1996510 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed reminders for half of eligible patients
Number of subjects: 686
Study 1996510 — intervention group
Group type: COMPARATOR
Intervention: No printed reminders
Number of subjects: 686
Study 6095655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 109
Study 6095655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg as a single nighttime dose
Number of subjects: 109
Study 31605515 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-based walking therapy
Number of subjects: 54
Study 31605515 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 54
Study 28393417 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg d1) in combination with granisetron and dexamethasone
Number of subjects: 645
Study 28393417 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant (125 mg d1; 80 mg d2-d3) in combination with granisetron and dexamethasone
Number of subjects: 645
Study 25844619 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplement (45-g daily)
Number of subjects: 208
Study 25844619 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextrin supplement (control)
Number of subjects: 208
Study 24517028 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1.0 g) co-administered with ferrous sulphate (300 mg)
Number of subjects: 10
Study 24517028 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1.0 g) alone
Number of subjects: 10
Study 22314714 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation (CSM)
Number of subjects: 12
Study 19508653 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (E)
Number of subjects: 63
Study 19508653 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (S)
Number of subjects: 63
Study 19508653 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE)
Number of subjects: 63
Study 19508653 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 63
Study 17544558 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet alone
Number of subjects: 503
Study 17544558 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet plus motivational quiz
Number of subjects: 503
Study 17544558 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet plus implementation intention prompt
Number of subjects: 503
Study 17544558 — intervention group
Group type: COMPARATOR
Intervention: No leaflet (control)
Number of subjects: 503
Study 15321812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked, puréed sweet potatoes (750 microg RE/d)
Number of subjects: 14
Study 15321812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked, puréed Indian spinach (Basella alba) (750 microg RE/d)
Number of subjects: 14
Study 15321812 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (750 microg RE/d)
Number of subjects: 14
Study 15321812 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic beta-carotene (750 microg RE/d)
Number of subjects: 14
Study 15321812 — intervention group
Group type: COMPARATOR
Intervention: Low-vitamin A control group (0 microg RE/d)
Number of subjects: 14
Study 12215864 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gallium-arsenide (Ga-As) laser therapy
Number of subjects: 75
Study 12215864 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline therapy (10 mg daily at bedtime for 8 weeks)
Number of subjects: 75
Study 12215864 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 75
Study 9831123 — intervention group
Group type: EXPERIMENTAL
Intervention: FC‐23 at 30% concentration
Number of subjects: 5
Study 9831123 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 5
Study 9831123 — intervention group
Group type: COMPARATOR
Intervention: 40% N2O
Number of subjects: 5
Study 7526675 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 78
Study 7526675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 78
Study 7526675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sematilide
Number of subjects: 78
Study 2782506 — intervention group
Group type: EXPERIMENTAL
Intervention: Television plus manual condition
Number of subjects: 50000
Study 2782506 — intervention group
Group type: COMPARATOR
Intervention: Manual alone
Number of subjects: 50000
Study 2782506 — intervention group
Group type: COMPARATOR
Intervention: Other conditions designed to supplement the manual plus television
Number of subjects: 50000
Study 780001 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol, 800 mcg daily
Number of subjects: 0